Wuyou Tiaodong Secures Nearly RMB 100 Million Series A Funding to Advance Comprehensive PFO Diagnosis and Treatment Solutions

1. The National Healthcare Security Administration Fully Promotes the Expansion and Quality Improvement of Immediate Settlement Reform for Medical Insurance Funds

Recently, according to the official website of the National Healthcare Security Administration, this year, healthcare security departments at all levels have taken proactive measures to accelerate the reform of instant settlement, achieving remarkable results. At the same time, it should be noted that there is still significant room for improvement in the coverage, mechanism construction, and basic management of the instant settlement reform. To further advance the reform of instant settlement, the National Healthcare Security Administration issued the "Notice on Comprehensively Promoting the Expansion and Quality Improvement of the Reform of Instant Settlement of Medical Insurance Funds." By the end of 2026, the goal is to achieve instant settlement funds accounting for more than 80% of the local medical insurance fund’s monthly settlement funds. The settlement funds will cover employee medical insurance funds (including maternity insurance) and urban and rural resident medical insurance funds. Regions with conditions can explore including critical illness insurance funds, medical assistance funds, etc., within the scope of instant settlement. The settlement funds will cover general outpatient services, outpatient services for chronic and special diseases, hospitalization, maternity, and pharmacy medication expenses. It can gradually explore incorporating cross-regional medical treatment costs into the scope of instant settlement. (People's Daily Online)

2. Tongji Hospital Collaborates on New Brain-Computer Interface Treatment for Parkinson's Disease

Recently, Tongji Hospital of Huazhong University of Science and Technology held a Brain-Computer Interface (BCI) Strategy Seminar and the First Working Meeting of the Research Institute. During the meeting, the hospital released its BCI development strategy blueprint and officially signed a strategic cooperation agreement with the Chinese BCI company "Neurodome," marking another significant link in the collaborative innovation chain between hospitals and enterprises. This collaboration between Tongji Hospital and "Neurodome" will continue under the dual-PI (Principal Investigator) system, driven by both clinicians and engineers, to jointly develop new therapeutic BCI solutions for Parkinson's disease, conduct clinical trials, and validate their safety and efficacy. It is reported that Tongji Hospital, relying on its comprehensive GCP platform and ethical review system, has provided full-process support for 15 BCI clinical research projects, forming one of the largest BCI clinical research clusters in China, covering the widest range of diseases. Meanwhile, the hospital has been approved to establish the first "BCI Medical Insurance Data Research Center" in China, conducting research on incorporating innovative technologies into the medical insurance payment system, bridging the "last mile" from technology to public welfare. (Jiemian News)

3. Hangzhou Heavyweight Policies Support Scientific and Technological Innovation

Recently, Hangzhou issued the "Implementation Plan for Optimizing the Innovation Ecosystem and Continuously Increasing Investment in Scientific and Technological Innovation in Hangzhou," which clearly states that by 2030, the city's investment in scientific and technological innovation will reach 400 billion yuan, with R&D expenditure intensity increasing to 4.5%. The plan will officially take effect on November 29. Currently, Hangzhou ranks 13th in the global top 100 innovation clusters of the Global Innovation Index, reaching a historical high. The "Plan" establishes a step-by-step development goal, aiming to achieve an investment of 300 billion yuan in scientific and technological innovation across the city by 2027. Funds will be precisely directed towards "four key areas," including research platforms and talent cultivation. The "Plan" also strengthens the leading role of enterprises in innovation, establishing a tiered cultivation system and setting up a direct investment fund for the transformation of scientific and technological achievements. Additionally, the new policy will accelerate the layout of future industries and make corresponding provisions to enhance the level of investment in scientific and technological innovation in universities, research institutes, and medical and health institutions. (Liangzhu Life Science Town)

4. Multiple Regions Compete in the Medical Device Track

Recently, the Beijing Drug and Medical Device Innovation Service Station (Haidian) was officially inaugurated, becoming the fourth municipal-level drug and medical device innovation service station in Beijing after Changping, Economic Development Zone (Yizhuang), and Daxing. This marks the official formation of a "Southeast-Northwest" coordinated layout for Beijing's drug and medical device innovation service network, further reducing the radius of policy services. Zhejiang Province held a special session for medical device matchmaking as part of its "Ten Chains, Hundred Venues, Ten Thousand Enterprises" series in Hangzhou, aiming to promote precise alignment between "clinical demand" and "product supply," facilitate the promotion and application channels of innovative medical enterprises, and achieve mutual empowerment and win-win cooperation between "clinical quality improvement" and "industrial foundation strengthening," ultimately benefiting both sides. The "Three Medicines Linkage" drives the medical device industry chain and value chain toward the mid-to-high end. Currently, China’s medical device industry is showing breakthroughs in multiple dimensions. From brain-computer interface systems to medical robots, from multi-modal coronary OCT systems to ultra-wide CTs, a series of cutting-edge products that fill domestic and international gaps have successively appeared on the international stage, competing head-to-head with traditional international giants like GE and Siemens. (Xinhua News Agency)

5. Billion-dollar medical device leader plans Hong Kong stock listing

Recently, Mindray Medical announced that, in order to meet the needs of business development, further promote its internationalization strategy, build an international capital operation platform, and enhance the company's capital strength, it has decided, after thorough research and discussion, to issue foreign-invested shares (H shares) overseas and list on the Main Board of the Hong Kong Stock Exchange. According to the investor relations activity record disclosed by Mindray Medical, in the first half of the year, the company achieved revenue of 16.743 billion yuan, a year-on-year decrease of 18.45%; net profit attributable to shareholders was 5.069 billion yuan, a year-on-year decrease of 32.96%. Preliminary calculations indicate that the overall revenue growth rate for the third quarter will turn positive year-on-year, while continuing to maintain the trend of quarterly sequential improvement in revenue. (China Securities Journal)

6. QView Medical and Eve Wellness Announce Partnership

Recently, QView Medical, an enterprise with FDA-approved artificial intelligence for breast ultrasound cancer detection, announced a strategic partnership with Eve Wellness, a company providing direct-to-consumer breast cancer screening. QView’s AI platform is integrated with GE’s Automated Breast Ultrasound (ABUS) system and has been deployed in over 100 locations, including hospitals in Chicago, Atlanta, Salt Lake City, and Los Angeles. Clinical studies show that the technology improves cancer detection rates, particularly in women with dense breast tissue, as density can obscure tumors in mammograms. Eve Wellness spent more than three years pioneering a patient-centered model to bring breast cancer screening directly to women. By combining QView’s FDA-approved AI with GE’s 3D whole-breast ultrasound technology, Eve can capture the entire breast, reducing the risk of missed cancer diagnoses. (AHHM)

7. R&D Design Services Accelerate the Clinical Transformation of Medical Research Achievements

The research and development of medical devices is a complex and rigorous process, involving multiple aspects such as technology, regulations, and clinical practices. Neurodome has a 20,000-square-meter science and innovation center and has established a medical device research institute dedicated to the clinical transformation of medical scientific research achievements. It boasts a high-level, international, multidisciplinary professional team proficient in the entire process of R&D, regulations, clinical trials, registration, and production, capable of developing and producing various complex and innovative products. With extensive project experience and industry resources, Neurodome has built a standardized, regulated, and digitalized full-process service system. It provides one-stop services from initial market research, product concept generation, product design and development to prototype production and testing. To date, Neurodome has had over 200 projects enter the review stage, more than 100 projects under development, with a 100% success rate in transformation. (Compiled by Neurodome)

8. Neurodome Completes Nearly 100 Million Yuan in Series A Financing

Recently, Worry-Free Heartbeat Medical Technology (Shenzhen) Co., Ltd. announced the completion of nearly RMB 100 million in Series A financing. This round of financing was led by Taiping Medical Health Fund, with Yangtze River Capital participating. The funds will be used to accelerate the industrialization and commercialization of a complete solution for Patent Foramen Ovale (PFO), enhance the innovative product portfolio in the field of structural heart disease, and fulfill the mission of "maximizing patients' quality of life and perfecting the last line of defense for life." With the successful completion of this round of financing, Worry-Free Heartbeat has formed a diversified shareholder lineup encompassing insurance capital, securities firms, industry listed companies, and venture capital institutions. (VcBeat)